MedTrace Logo

Intravenous Treatments Used in Medication Overuse Headache Bridge Treatment

NCT05608642 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2022-11-08

No results posted yet for this study

Summary

Medication overuse headache is the chronicity of headaches, which occurs more than 15 days a month, as a result of frequent use of painkillers, opioids or migraine attack drugs (ergotamine, triptan) in individuals with pre-existing primary headache disease.

In the treatment of this headache, two ways can be followed as slow drug discontinuation or sudden drug discontinuation. The most commonly used method is the sudden discontinuation of the overused analgesic agent, the initiation of prophylactic treatment, and then the application of bridge therapy for 6-10 days. Intravenous hydration, steroids, antiemetics, neuroleptic drugs and local anesthetic drugs such as lidocaine can be used in bridge treatment.

Conditions

  • Medication Overuse Headache

Interventions

OTHER

Intravenous hydration

500 cc intravenous serum for 1 hour in the first group service consists of patients who have been given.

OTHER

Intravenous prednisolone

The second group consisted of patients who were given 80 mg intravenous prednisolone for the first 4 days and then gradually reduced doses of prednisolone in the following days.

OTHER

Intravenous lidocaine

The third group includes patients in whom 2 mg/kg of intravenous lidocaine is given by 1-hour infusion.

Sponsors & Collaborators

  • Diskapi Teaching and Research Hospital

    lead OTHER

Principal Investigators

  • Ömer Taylan Akkaya · Diskapi Yildirim Beyazıt Teaching and Research Hospital

  • Gevher Rabia Genç Perdecioğlu · Diskapi Yildirim Beyazıt Teaching and Research Hospital

  • Hüseyin Alp Alptekin · Diskapi Yildirim Beyazıt Teaching and Research Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-22
Primary Completion
2023-11-30
Completion
2023-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05608642 on ClinicalTrials.gov